
NASDAQHealthcareMedical - Diagnostics & Research
أحدث البيانات المتاحة
164.17 US$
−0.33 US$ · -0.20%
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
الإغلاق السابق
164.17 US$
−0.33 US$ · -0.20%
بعد ساعات التداول
164.17 US$
0.00 US$ · 0.00%
9 أكتوبر، 7:30 م ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
نطاق اليوم
السعر الحالي 164.17 US$
نطاق 52 أسبوعًا
السعر الحالي 164.17 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
79
أقل من القيمة
المشاعر
54
مختلط
المخاطر
50
مخاطر أعلى من المعتاد
الزخم
51
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
نطاق اليوم
السعر الحالي 164.17 US$
نطاق 52 أسبوعًا
السعر الحالي 164.17 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 8.25 مليار USD | 8.28 مليار USD | 8.12 مليار USD | 7.74 مليار USD | 5.48 مليار USD |
| تكلفة البضاعة المباعة | 6.08 مليار USD | 5.85 مليار USD | 5.72 مليار USD | 5.53 مليار USD | 3.97 مليار USD |
| الربح الإجمالي | 2.18 مليار USD | 2.44 مليار USD | 2.4 مليار USD | 2.21 مليار USD | 1.51 مليار USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 780.14 مليون USD | 728.35 مليون USD | 776.36 مليون USD | 778.75 مليون USD | 585.33 مليون USD |
| نفقات التشغيل | 1.16 مليار USD | 1.34 مليار USD | 1.44 مليار USD | 1.42 مليار USD | 1.13 مليار USD |
| دخل الفوائد | 7.11 مليون USD | 8.61 مليون USD | 5.01 مليون USD | 2.35 مليون USD | 574 ألف USD |
| مصاريف الفوائد | 188.11 مليون USD | 237.24 مليون USD | 336.7 مليون USD | 229.73 مليون USD | 182.42 مليون USD |
| الاستهلاك والإطفاء | 383 مليون USD | 488.5 مليون USD | 585.95 مليون USD | 569.51 مليون USD | 314.99 مليون USD |
| الدخل التشغيلي | 1.01 مليار USD | 1.1 مليار USD | 956.15 مليون USD | 795.24 مليون USD | 378.53 مليون USD |
| صافي الدخل | 229.34 مليون USD | 791.47 مليون USD | 612.34 مليون USD | 505.3 مليون USD | 153.19 مليون USD |
تم تحديث حقائق الشركة 10 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
173.82 US$
ارتفاع محتمل بنسبة 5.88%المحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.